NEW YORK, April 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Newmont Mining Corporation (NYSE: NEM), The Bank of New York Mellon Corporation (NYSE: BK), Tyson Foods, Inc. (NYSE: TSN), Covidien plc (NYSE: COV), and Questcor Pharmaceuticals Inc. (NASDAQ: QCOR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Newmont Mining Corporation Analyst Notes
On April 1, 2014, Newmont Mining Corporation (Newmont) announced the closing of its previously announced five-year, amortizing term loan of $575 million which will be used to repay the debt maturing in July 2014. The Company also renewed its $3.0 billion corporate revolving credit facility, extending the maturity date two years to March 31, 2019. Commenting on the development, Laurie Brlas, Executive Vice President and CFO, said, "The term loan allows us to repay the 2014 maturities and provides the flexibility to reduce debt over the coming years. Extending the maturity of our revolving credit facility ultimately enhances our corporate liquidity profile." Both bank facilities are unsecured and include a single financial covenant requiring a net-debt-to-capitalization ratio below 0.63. As of December 31, 2013, the Company's leverage ratio, as defined, was 0.29. The full analyst notes on Newmont Mining Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04042014/NEM/report.pdf
--
The Bank of New York Mellon Corporation Analyst Notes
On April 1, 2014, The Bank of New York Mellon Corporation (BNY Mellon) announced that it will release its Q1 2014 financial results on April 22, 2014 at 6:30 a.m. EDT. Gerald L. Hassell, Chairman and CEO, and Thomas P. Gibbons, Vice Chairman and CFO, along with other members of executive management from BNY Mellon will also host a conference call to discuss the financial performance at 8:00 a.m. EDT on the same day. The stock closed at $35.41, up 0.34% from its previous day's close. The Company had recently announced that the U.S. Federal Reserve has approved its 2014 capital plan, paving way for repurchase of up to $1.74 billion of its common stock and 13% increase in quarterly common stock dividend. While the share repurchase proposal has already received BNY Mellon Board's approval, the dividend increase is expected to be considered at a meeting in April 2014. The full analyst notes on The Bank of New York Mellon Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04042014/BK/report.pdf
--
Tyson Foods, Inc. Analyst Notes
On March 28, 2014, Tyson Foods, Inc. (Tyson) announced that the Forbes Magazine has named the Company as one of the 2014 "America's 100 Most Trustworthy Companies." The recognition comes soon after the Company was honored by the Fortune Magazine among "America's Most Admired Companies" in February 2014. "Recognition of this sort is always appreciated. It reflects well on the thousands of Tyson Foods team members who make up our company," said Sara Lilygren, Executive Vice President of Corporate Affairs for Tyson Foods. The full analyst notes on Tyson Foods, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/TSN/report.pdf
--
Covidien plc Analyst Notes
On March 28, 2014, Covidien plc (Covidien) announced that it is teaming up with AORN Foundation for an initiative which will provide nursing professionals with a core set of financial and management tools to complement their clinical expertise. The initiative will comprise five day-long seminars focusing on leadership development and financial concepts necessary for managing the overall performance of perioperative services. "Nurses are on the frontlines of care, and increasingly find themselves at the intersection of improving patient outcomes in a lower cost environment," said Matt Gattuso, President of health systems at Covidien and an AORN Foundation board member. The full analyst notes on Covidien plc are available to download free of charge at:
http://www.AnalystsReview.com/04042014/COV/report.pdf
--
Questcor Pharmaceuticals Inc. Analyst Notes
On April 1, 2014, the stock of Questcor Pharmaceuticals Inc. (Questcor) closed at its highest level in over a month at $69.47, representing a gain of 6.99% from previous day's close. The stock opened the session at $65.50, and traded in the range of $65.12 - $69.70, with a total of 2.56 million shares changing hands. The rise was in line with the NASDAQ Biotechnology Index which ended the session higher by 2.13% at 2,521.47. Questcor's stock has gained 14.35% in last one month, outperforming the NASDAQ Biotechnology Index (ETF) which lost 8.8% during the same period. Questcor is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The full analyst notes on Questcor Pharmaceuticals Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/QCOR/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
